The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).
A year later after publishing the results from its first Phase 3 trial (MAPP1), MAPS announced that MAPP2 is expected to reach completion by October 2022, enabling the organization to then file a New Drug Application with the FDA in the first half of 2023.
If the FDA were to grant the New Drug status, commercialization of the substance would mean a more than interesting opportunity for companies such as Field Trip (NASDAQ: FTRP), Atai (NASDAQ: ATAI) and MindMed (NASDAQ: MNMD).
MAPP2 will develop in 13 different sites in the United States and Israel with the goal of studying whether MDMA is a viable treatment for PTSD. The study will consist of three 90-minute preparatory sessions, three eight-hour MDMA-assisted therapy sessions and at least nine 90-minute integration sessions.
In a press release, MAPS noted that “among Americans exposed to trauma, people of color and LGBTQ+ individuals are more likely to develop PTSD, yet less likely to receive a diagnosis or have reasonable access to treatment.” For that reason, MAPS has established equity initiatives in therapist training and in participant recruitment.
Amy Emerson, CEO of MAPS PBC, said: “We are eagerly awaiting the possibility that our scientific inquiry may be confirmed in this critically important trial scheduled to be completed in October 2022.”
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.